The Role of Interleukin-6 in Alcoholic Liver Disease
The Role of Interleukin-6 in Alcoholic Liver Disease
复制标题
DOI：
10.13865/j.cnki.cjbmb.2020.10.1414
复制
发表时间：
2021-04-01
期刊：
影响因子：
--
通讯作者：
Cui Di
中科院分区：
文献类型：
--
作者：
Cui Wei;Cui Di
酒精性肝病（ALD）是一种长期过量饮酒引起的肝脏内部组织炎症损害的慢性肝病。乙醇及其衍生物在代谢过程中直接或间接诱导肝脏炎症反应可能是ALD的重要机制，但这一过程的潜在细胞和分子机制尚不清楚。最近的研究发现，白细胞介素-6 （IL-6）对乙醇介导的肝细胞炎症反应具有双重作用。它参与炎症过程，驱动酒精损伤，激活细胞凋亡信号通路刺激巨噬细胞和淋巴细胞急性反应蛋白合成，加重炎症反应，并可导致肝细胞再生，增加抗炎细胞因子水平，发挥抗炎功能，改善肝损伤程度，而运动应激可引起肌源性IL-6暂时性显著升高。改变肝脏氧化-炎症状态。然后使机体长期处于抗炎的适应性状态，防止肝细胞的炎症损伤。在加深对ALD炎症病理机制认识的同时，对酒精性肝细胞炎症相关因子变化及IL-6调控通路进行综述，考虑到临床应用IL-6联合炎症因子通路靶向治疗有望成为一种新颖的治疗方法，实验室筛选炎症相关ALD药物干预的可行性；为酒精性肝病的预防和治疗提供新的靶点和思路。
Alcoholic liver disease ( ALD) is a chronic liver disease in which the internal liver tissues are inflammation damaged caused by long-term excessive drinking. Direct or indirect induction of hepatic inflammatory response by ethanol and its derivatives in the metabolic process may be an important mechanism of ALD, but the underlying cellular and molecular mechanisms of this process are still unclear. Recent study found that interleukin-6 (IL-6) response to ethanol mediated inflammation of the liver cells with dual role. It is involved in an inflammatory process that drives alcohol damage, activate cell apoptosis signaling pathways to stimulate macrophage and lymphocyte acute reactive protein synthesis aggravate the inflammatory response, and can lead to liver cell regeneration, increase anti-inflammatory cytokine levels play anti-inflammatory function to improve the degree of liver injury, and exercise stress can cause muscle source sex IL-6 temporary increased significantly, change the liver oxidation-inflammatory state. Then the body is kept in the adaptive state of long-term anti-inflammation to prevent the inflammatory damage of liver cells. Based on deepening the understanding of ALD inflammation pathological mechanism at the same time, the review on alcoholic liver cell inflammation related factor change and the IL-6 regulation pathway, considering the clinical use of IL-6 joint inflammatory factor pathway of targeted therapy is expected to be a novel therapy , the feasibility for laboratory screening of inflammatory related ALD drug intervention, for the prevention of alcoholic liver disease and treatment to provide new targets and train of thought.